The combination of fludarabine and cyclophosphamide prior to anti-CD19 CAR-T-cell infusion has been shown to improve CAR-T-cell functionality and clinical outcomes, a phenomenon also seen in other hematological malignancies (277). The gene discussed is CD19; the disease is hematologic disorder.